These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 12902485)

  • 21. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
    Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10.
    Willemsen RA; Sebestyén Z; Ronteltap C; Berrevoets C; Drexhage J; Debets R
    J Immunol; 2006 Jul; 177(2):991-8. PubMed ID: 16818755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro priming with adenovirus/gp100 antigen-transduced dendritic cells reveals the epitope specificity of HLA-A*0201-restricted CD8+ T cells in patients with melanoma.
    Linette GP; Shankara S; Longerich S; Yang S; Doll R; Nicolette C; Preffer FI; Roberts BL; Haluska FG
    J Immunol; 2000 Mar; 164(6):3402-12. PubMed ID: 10706736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An antigen-targeted approach to adoptive transfer therapy of cancer.
    Valmori D; Pittet MJ; Rimoldi D; Liénard D; Dunbar R; Cerundolo V; Lejeune F; Cerottini JC; Romero P
    Cancer Res; 1999 May; 59(9):2167-73. PubMed ID: 10232604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers.
    Savage P; Millrain M; Dimakou S; Stebbing J; Dyson J
    Tumour Biol; 2007; 28(2):70-6. PubMed ID: 17264539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function.
    Schmid DA; Irving MB; Posevitz V; Hebeisen M; Posevitz-Fejfar A; Sarria JC; Gomez-Eerland R; Thome M; Schumacher TN; Romero P; Speiser DE; Zoete V; Michielin O; Rufer N
    J Immunol; 2010 May; 184(9):4936-46. PubMed ID: 20351194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
    Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
    J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human antitumor CD8+ T cells producing Th1 polycytokines show superior antigen sensitivity and tumor recognition.
    Wilde S; Sommermeyer D; Leisegang M; Frankenberger B; Mosetter B; Uckert W; Schendel DJ
    J Immunol; 2012 Jul; 189(2):598-605. PubMed ID: 22689880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel soluble HLA-A2/MELAN-A complexes selectively stain a differentiation defective subpopulation of CD8+ T cells in patients with melanoma.
    Guillaume P; Baumgaertner P; Neff L; Rufer N; Wettstein P; Speiser DE; Luescher IF
    Int J Cancer; 2010 Aug; 127(4):910-23. PubMed ID: 19998338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence.
    Gannon PO; Wieckowski S; Baumgaertner P; Hebeisen M; Allard M; Speiser DE; Rufer N
    J Immunol; 2015 Jul; 195(1):356-66. PubMed ID: 26002978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.
    Rivoltini L; Castelli C; Carrabba M; Mazzaferro V; Pilla L; Huber V; Coppa J; Gallino G; Scheibenbogen C; Squarcina P; Cova A; Camerini R; Lewis JJ; Srivastava PK; Parmiani G
    J Immunol; 2003 Oct; 171(7):3467-74. PubMed ID: 14500642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
    Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
    Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
    Benlalam H; Linard B; Guilloux Y; Moreau-Aubry A; Derré L; Diez E; Dreno B; Jotereau F; Labarrière N
    J Immunol; 2003 Dec; 171(11):6283-9. PubMed ID: 14634146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
    Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
    Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
    Yang S; Linette GP; Longerich S; Haluska FG
    J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro.
    Fleischer K; Schmidt B; Kastenmüller W; Busch DH; Drexler I; Sutter G; Heike M; Peschel C; Bernhard H
    J Immunol; 2004 Jan; 172(1):162-9. PubMed ID: 14688322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.
    Speiser DE; Baumgaertner P; Barbey C; Rubio-Godoy V; Moulin A; Corthesy P; Devevre E; Dietrich PY; Rimoldi D; Liénard D; Cerottini JC; Romero P; Rufer N
    J Immunol; 2006 Jul; 177(2):1338-48. PubMed ID: 16818795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.
    Ayyoub M; Stevanovic S; Sahin U; Guillaume P; Servis C; Rimoldi D; Valmori D; Romero P; Cerottini JC; Rammensee HG; Pfreundschuh M; Speiser D; Lévy F
    J Immunol; 2002 Feb; 168(4):1717-22. PubMed ID: 11823502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8+ T cells in melanoma patients.
    Valmori D; Dutoit V; Liénard D; Lejeune F; Speiser D; Rimoldi D; Cerundolo V; Dietrich PY; Cerottini JC; Romero P
    J Immunol; 2000 Jul; 165(1):533-8. PubMed ID: 10861093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
    Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
    J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.